Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

See our updated masking policy »

Stanford Health Care

Influence of insurance status on the postoperative outcomes of cytoreductive surgery and HIPEC. Journal of surgical oncology Kubi, B., Nudotor, R., Fackche, N., Rowe, J., Cloyd, J. M., Ahmed, A., Grotz, T. E., Fournier, K., Dineen, S., Veerapong, J., Baumgartner, J. M., Clarke, C., Patel, S. H., Dhar, V., Lambert, L., Abbott, D. E., Pokrzywa, C., Raoof, M., Lee, B., Zaidi, M. Y., Maithel, S. K., Johnston, F. M., Greer, J. B. 2022

Abstract

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is increasingly performed for peritoneal surface malignancies but remains associated with significant morbidity. Scant research is available regarding the impact of insurance status on postoperative outcomes.Patients undergoing CRS/HIPEC between 2000 and 2017 at 12 participating sites in the US HIPEC Collaborative were identified. Univariate and multivariate analyses were used to compare the baseline characteristics, operative variables, and postoperative outcomes of patients with government, private, or no insurance.Among 2268 patients, 699 (30.8%) had government insurance, 1453 (64.0%) had private, and 116 (5.1%) were uninsured. Patients with government insurance were older, more likely to be non-white, and comorbid (p?15, completeness of cytoreduction score >1, and nonhome discharge were factors independently associated with a postoperative complication.While there were differences in postoperative outcomes between the three insurance groups on univariate analysis, there was no independent association between insurance status and postoperative complications after CRS/HIPEC.

View details for DOI 10.1002/jso.27147

View details for PubMedID 36468401